Understanding how Galectin-3 affects Graft vs. Host Disease and Graft vs. Tumor responses
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses
This study is looking at how a protein called Galectin-3 affects the immune responses in patients who have received a stem cell transplant, with the hope of finding ways to reduce complications like Graft vs. Host Disease and improve recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10857141 on NIH RePORTER |
What this research studies
This research investigates the role of Galectin-3 in regulating Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) responses in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). By studying both murine models and human patients, the research aims to uncover how Galectin-3 influences immune responses and potentially mitigates the severity of GvHD. The approach includes examining the cellular mechanisms of Galectin-3 signaling and its effects on donor and recipient immune cells. This could lead to new therapeutic strategies to improve patient outcomes after transplantation.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients undergoing allogeneic hematopoietic cell transplantation for conditions like leukemia, lymphoma, or severe anemia.
Not a fit: Patients who are not undergoing allo-HCT or those with conditions unrelated to GvHD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of Graft vs. Host Disease, enhancing the safety and effectiveness of stem cell transplants for patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune regulators like Galectin-3, indicating potential for success in this novel approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Mohammadpour, Hemn — Roswell Park Cancer Institute Corp
- Study coordinator: Mohammadpour, Hemn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.